Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Merit Medical Systems ( (MMSI) ) has provided an update.
On January 8, 2026, Merit Medical Systems announced that its board appointed longtime director and former Lead Independent Director F. Ann Millner as Chair of the Board, effective January 5, 2026, following the January 4, 2026 resignation of company founder Fred P. Lampropoulos as director and Chair, which came after his earlier departure as President and CEO on October 3, 2025 and conclusion as Executive Chair on January 3, 2026. The company emphasized that Lampropoulos’ departure was not due to any disagreement over governance, operations, or financial reporting and that he will continue to advise Merit under a consulting agreement through March 31, 2026, helping to provide continuity as the board also reduced its size from eleven to ten members; at the same time, Merit reported strong preliminary unaudited fourth-quarter 2025 revenue of $389 million to $395 million, up about 10% to 11% year over year, signaling solid operational momentum during the leadership transition.
The most recent analyst rating on (MMSI) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on Merit Medical Systems stock, see the MMSI Stock Forecast page.
Spark’s Take on MMSI Stock
According to Spark, TipRanks’ AI Analyst, MMSI is a Neutral.
Merit Medical Systems’ overall stock score is driven by strong financial performance and positive earnings call insights, indicating robust growth prospects. However, technical analysis suggests bearish trends, and the stock’s high valuation limits its appeal. Monitoring operational costs and market conditions is recommended.
To see Spark’s full report on MMSI stock, click here.
More about Merit Medical Systems
Merit Medical Systems, Inc., founded in 1987, is a global healthcare technology company that develops, manufactures, and distributes proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, with key focus areas including cardiology, radiology, oncology, critical care, and endoscopy. The company serves customers worldwide through a large domestic and international sales and clinical support force of more than 800 professionals and employs approximately 7,500 people globally.
Average Trading Volume: 612,252
Technical Sentiment Signal: Buy
Current Market Cap: $5.52B
For detailed information about MMSI stock, go to TipRanks’ Stock Analysis page.